The combined treatment of desipramine, a tricyclic antidepressant known to significantly improve survival rates in cancer patients, and abemaciclib, a CDK4/6 inhibitor applicable to various cancer types, induces a significantly synergistic effect in colorectal cancer therapy without noticeable side effects from abemaciclib. Here, CDK4 is linked to cancer.